RxDoctor Payments Data

Alla Roitman, DO

Internal Medicine · Hackensack, NJNPI 1699093054

Payments from drug & device makers

$1,708in general payments, 2019–2025

Across 63 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$299
  • Novo Nordisk$285
  • Inspire Medical Systems, Inc.$227
  • AstraZeneca$156
  • Regeneron Healthcare Solutions, Inc.$124
  • Mannkind Corporation$123
  • plus $493 from 7 others

What the payments were for

  • Food & beverage$1,60894%
  • Gifts$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,708 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$37,468
Medicare patients
120
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$33,700
OzempicSemaglutide18$23,693
MounjaroTirzepatide22$22,635
Icosapent Ethyl14$2,335
Rosuvastatin Calcium60$706
Pregabalin12$586
Atorvastatin Calcium53$454
Metoprolol Succinate32$418
Fluticasone Propionate21$338
Pantoprazole Sodium20$317
Ezetimibe15$299
Amlodipine Besylate44$275
Losartan Potassium25$261
Simvastatin18$250
Omeprazole17$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$63$33,70032 claims
Novo NordiskOzempic$285$23,69318 claims
Lilly USA, LLCMounjaro$299$22,63522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →